2-羟基-1-(吡咯烷-1-基)乙酮 | 45657-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-羟基-1-(吡咯烷-1-基)乙酮
• 英文名称: 2-hydroxy-1-(pyrrolidin-1-yl)ethanone
• 英文别名: 4-hydroxyacetylpiperidine；1-glycolylpyrrolidine；2-Hydroxy-1-(pyrrolidin-1-yl)ethan-1-one；2-hydroxy-1-pyrrolidin-1-ylethanone
• CAS: 45657-97-4
• 化学式: C₆H₁₁NO₂
• mdl: MFCD10048469
• 分子量: 129.159
• InChiKey: RWGVUODVPQFWCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  40 °C
• 沸点：
  281.8±23.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-羟基-1-(吡咯烷-1-基)乙酮 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.41h， 生成 Glyoxylsaeure-pyrrolidid
  参考文献：
  名称：

  Transition State-Based Sialyltransferase Inhibitors: Mimicking Oxocarbenium Ion by Simple Amide

  摘要：

  In the new transition-state based sialyltransferase inhibitors, an amide group was placed at the corresponding C-2 position of CMP-sialic acid to mimic the geometry and charge distribution in the transition state, and simple aromatic or aliphatic rings were used instead of the sialic acid moiety. All synthetic compounds exhibited excellent a(2-6)-sialyltransferase inhibition, resulting in up to a 2600-fold higher affinity for the enzyme than CMP-Neu5Ac, suggesting that amide is a key element for simulating transition-state

  DOI：

  10.1021/acs.jmedchem.6b01644
• 作为产物：
  描述：

  四氢吡咯 、 羟乙酸甲酯 反应 96.0h， 以100%的产率得到2-羟基-1-(吡咯烷-1-基)乙酮
  参考文献：
  名称：

  Transition State-Based Sialyltransferase Inhibitors: Mimicking Oxocarbenium Ion by Simple Amide

  摘要：

  In the new transition-state based sialyltransferase inhibitors, an amide group was placed at the corresponding C-2 position of CMP-sialic acid to mimic the geometry and charge distribution in the transition state, and simple aromatic or aliphatic rings were used instead of the sialic acid moiety. All synthetic compounds exhibited excellent a(2-6)-sialyltransferase inhibition, resulting in up to a 2600-fold higher affinity for the enzyme than CMP-Neu5Ac, suggesting that amide is a key element for simulating transition-state

  DOI：

  10.1021/acs.jmedchem.6b01644

文献信息

• Substituted piperidines as therapeutic compounds
  申请人：Speedel Experimenta AG

  公开号：EP2018862A1

  公开（公告）日：2009-01-28

  Described are compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R2, R3, W,and X have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

  描述了一般式（I）的化合物及其药用可接受的盐，其中R2、R3、W和X的定义在描述中详细说明，作为β-分泌酶、半胱氨酸蛋白酶D、质体蛋白酶II和/或HIV蛋白酶抑制剂。
• [EN] PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDINE ET LEURS ANALOGUES AZA EN TANT QU'INHIBITEURS DE TYK2
  申请人：CELLZOME LTD

  公开号：WO2012062704A1

  公开（公告）日：2012-05-18

  The present invention relates to compounds of formula (I), wherein R1 to R3, X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.

  本发明涉及式(I)的化合物，其中R1至R3，X1，X2的含义如描述和权利要求中所述。所述化合物可用作TYK2抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导性疾病。该发明还涉及包括所述化合物的药物组合物，以及它们作为药物的用途。
• Synthesis of 7-oxa-phomopsolide E and its C-4 epimer
  作者：Miaosheng Li、Jana Scott、George A. O’Doherty

  DOI：10.1016/j.tetlet.2003.11.089

  日期：2004.1

  A flexible, enantioselective route to highly functionalized α,β-unsaturated δ-lactones has been applied to the synthesis of 7-oxa-phomopsolide E and its C-4 epimer. This approach relies on the application of the Noyori asymmetric hydrogenation of furyl ketone to produce the secondary furyl alcohol in high enantioexcess, which can be stereoselectively transformed into α,β-unsaturated-δ-lactones by a

  灵活，对映选择性的途径可高度官能化的α，β-不饱和δ-内酯已被用于7-氧杂磷光固体E及其C-4差向异构体的合成。该方法依赖于应用Noyori呋喃酮不对称氢化来生产高对映体过量的仲呋喃醇，后者可以通过短的，高度非对映选择性的氧化和还原序列立体选择性地转化为α，β-不饱和δ-内酯。DCC和Mitsunobu偶联用于引入两个天然产物类似物的侧链。
• SUBSTITUTED HYDANTOINS
  申请人：Chen Shaoqing

  公开号：US20090048452A1

  公开（公告）日：2009-02-19

  This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.

  这项发明涉及以下式I的化合物： 或其药用可接受的盐， 其中R1、R2、R3、R4、R5和R6在本申请中有描述。这些化合物抑制MEK 1和MEK2酶，这是MAP激酶信号转导途径的组成部分，因此这些化合物将具有抗高增殖细胞活性。
• [EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER AU MOYEN D'AMIDES D'ACIDE O-AMINO-ALCANOIQUE A SUBSTITUTIONS AROMATIQUES ET DE DIAMIDES D'ACIDE ALCANOIQUE
  申请人：ELAN PHARM INC

  公开号：WO2003103652A1

  公开（公告）日：2003-12-18

  Disclosed.are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R1, R2, R3, R4, R5, X1, and X2 are defined herein.

  披露了治疗阿尔茨海默病和其他疾病，和/或抑制β-分泌酶酶，和/或通过使用式(I)化合物在哺乳动物体内抑制Aβ肽沉积的方法，其中变量R1、R2、R3、R4、R5、X1和X2在此处定义。